NO20085290L - Metode - Google Patents

Metode

Info

Publication number
NO20085290L
NO20085290L NO20085290A NO20085290A NO20085290L NO 20085290 L NO20085290 L NO 20085290L NO 20085290 A NO20085290 A NO 20085290A NO 20085290 A NO20085290 A NO 20085290A NO 20085290 L NO20085290 L NO 20085290L
Authority
NO
Norway
Prior art keywords
mage
relates
probes
methods
specific
Prior art date
Application number
NO20085290A
Other languages
English (en)
Norwegian (no)
Inventor
Thierry Coche
Gabriele Annemarie Beer
Olivier Gruselle
Dennis Salonga
Craig Lawrence Stephens
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of NO20085290L publication Critical patent/NO20085290L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Manufacturing & Machinery (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO20085290A 2006-06-21 2008-12-18 Metode NO20085290L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0612342.6A GB0612342D0 (en) 2006-06-21 2006-06-21 Method
PCT/EP2007/056219 WO2007147876A2 (en) 2006-06-21 2007-06-21 Method for the detection and diagnosis of cancer involving primers and probes for the specific detection of the mage- a3 -marker

Publications (1)

Publication Number Publication Date
NO20085290L true NO20085290L (no) 2009-01-19

Family

ID=36803668

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20085290A NO20085290L (no) 2006-06-21 2008-12-18 Metode

Country Status (28)

Country Link
US (1) US8936919B2 (pl)
EP (1) EP2041308B1 (pl)
JP (2) JP2009540812A (pl)
KR (1) KR101455589B1 (pl)
CN (1) CN101506383B (pl)
AU (1) AU2007263019B2 (pl)
BR (1) BRPI0713599A2 (pl)
CA (1) CA2656909A1 (pl)
CO (1) CO6140072A2 (pl)
CY (1) CY1113290T1 (pl)
DK (1) DK2041308T3 (pl)
EA (1) EA016347B1 (pl)
ES (1) ES2389513T3 (pl)
GB (1) GB0612342D0 (pl)
HK (1) HK1127627A1 (pl)
HR (1) HRP20120761T1 (pl)
IL (1) IL195975A (pl)
MA (1) MA30565B1 (pl)
MX (1) MX2008016493A (pl)
MY (1) MY147511A (pl)
NO (1) NO20085290L (pl)
NZ (1) NZ573809A (pl)
PL (1) PL2041308T3 (pl)
PT (1) PT2041308E (pl)
SI (1) SI2041308T1 (pl)
UA (1) UA95956C2 (pl)
WO (1) WO2007147876A2 (pl)
ZA (1) ZA200810695B (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101932723B (zh) 2007-09-17 2014-09-10 肿瘤甲基化科学公司 改进的对mage-a表达的检测
US8987423B2 (en) * 2010-07-22 2015-03-24 Glaxosmithkline Biologicals, S.A. MAGE antigen binding proteins
CN102251033B (zh) * 2011-07-05 2013-03-20 北京大学人民医院 基于mage-a3基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612201A (en) * 1991-05-23 1997-03-18 Ludwig Institute For Cancer Research Isolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursor
IL106610A0 (en) * 1992-08-07 1993-12-08 Cytel Corp Hla binding peptides and their uses
DE69524264T2 (de) * 1994-03-01 2002-07-18 Ludwig Inst Cancer Res Bestimmung krebsartiger beschaffenheiten durch die genexpression eines mitgliedes der melanomartigengruppe, mage
US5985571A (en) * 1998-02-04 1999-11-16 Ludwig Institute For Cancer Research Method for determining multiple myeloma by assaying for expression of mage genes
DK1659178T3 (da) * 1998-02-05 2010-07-12 Glaxosmithkline Biolog Sa Fremgangsmåde til oprensning eller fremstilling af et MAGE-protein
US6710172B1 (en) 1998-10-02 2004-03-23 Ludwig Institute For Cancer Research Tumor antigens and CTL clones isolated by a novel procedure
JP3603138B2 (ja) * 2000-02-18 2004-12-22 独立行政法人理化学研究所 細胞死抑制タンパク質
US6358679B1 (en) * 2000-08-24 2002-03-19 Pe Corporation (Ny) Methods for external controls for nucleic acid amplification
US6635425B2 (en) * 2001-01-05 2003-10-21 Molecular Staging, Inc. 5′-thio phosphate directed ligation of oligonucleotides and use in detection of single nucleotide polymorphisms
WO2003045427A2 (en) * 2001-11-29 2003-06-05 Dandrit Biotech A/S Pharmaceutical composition for inducing an immune response in a human or animal
DK1572105T3 (da) * 2002-11-14 2011-10-17 Wayne John Cancer Inst Detektion af mikrometastase af melamoner og brystcancer i paraffinindlejret tumor drænende lymfeknuder ved hjælp af kvantitativ multimaker RT-PCR
JP2006507841A (ja) 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
GB0409940D0 (en) * 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
US20070231822A1 (en) * 2006-02-28 2007-10-04 Michael Mitas Methods for the detection and treatment of cancer

Also Published As

Publication number Publication date
MA30565B1 (fr) 2009-07-01
ZA200810695B (en) 2014-03-26
KR20090034900A (ko) 2009-04-08
BRPI0713599A2 (pt) 2012-11-06
GB0612342D0 (en) 2006-08-02
KR101455589B1 (ko) 2014-10-28
AU2007263019B2 (en) 2012-11-08
ES2389513T3 (es) 2012-10-26
EP2041308B1 (en) 2012-07-11
EA200802356A1 (ru) 2009-06-30
UA95956C2 (uk) 2011-09-26
AU2007263019A1 (en) 2007-12-27
WO2007147876A2 (en) 2007-12-27
IL195975A0 (en) 2009-09-01
EP2041308A2 (en) 2009-04-01
US20120040341A1 (en) 2012-02-16
IL195975A (en) 2012-08-30
CN101506383A (zh) 2009-08-12
HRP20120761T1 (hr) 2012-10-31
MX2008016493A (es) 2009-05-21
MY147511A (en) 2012-12-31
JP5705191B2 (ja) 2015-04-22
JP2009540812A (ja) 2009-11-26
CO6140072A2 (es) 2010-03-19
CN101506383B (zh) 2013-08-28
CY1113290T1 (el) 2016-04-13
CA2656909A1 (en) 2007-12-27
PL2041308T3 (pl) 2012-11-30
PT2041308E (pt) 2012-10-09
WO2007147876A3 (en) 2008-05-15
HK1127627A1 (en) 2009-10-02
SI2041308T1 (sl) 2012-10-30
NZ573809A (en) 2011-12-22
JP2013046630A (ja) 2013-03-07
US8936919B2 (en) 2015-01-20
EA016347B1 (ru) 2012-04-30
DK2041308T3 (da) 2012-10-08

Similar Documents

Publication Publication Date Title
EA200802242A1 (ru) Способ определения того, будет или не будет пациент респондером на иммунотерапию
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
AU2008298744A8 (en) MiRNA expression in human peripheral blood microvesicles and uses thereof
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
EP1784639A4 (en) PROCESS FOR PREPARING FREEZERTED BLOOD PLATES, FLUIDIZED BLOOD PLATES, COMPOSITIONS AND USE METHOD
WO2010017515A3 (en) Breast cancer specific markers and methods of use
NO20084546L (no) Diagnostikk og behandlinger for tumorer
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
WO2007109236A3 (en) Microrna fingerprints during human megakaryocytopoiesis
WO2007081680A3 (en) Microrna expression abnormalities in pancreatic endocrine and acinar tumors
IL182423A0 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
EP3683320A3 (en) Mirna fingerprint in the diagnosis of lung cancer
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
WO2007081740A3 (en) Micrornarna-based methods and compositions for the diagnosis and treatment of solid cancers
TW200740844A (en) Novel MAdCAM antibodies
NO20071791L (no) Preparater og fremgangsmater for diagnostiseringen og behandlingen av tumor
MX348362B (es) Composiciones y metodos para tratar y diagnosticar asma.
EA200802182A1 (ru) Модифицированные гуманизированные антитела против интерлейкина-18
WO2007141280A3 (en) Proteins
WO2010059969A3 (en) Use of anti-vegf antibody in combination with chemtherapy for treating breast cancer
WO2009143181A3 (en) Micro-rna profile in human saliva and its use for detection of oral cancer
MX339340B (es) Metodos para predecir y mejorar la supervivencia de pacientes con cancer gastrico.
WO2007123722A3 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
EA201290107A1 (ru) Способ определения пациента как восприимчивого или не восприимчивого к иммунотерапии
NO20085290L (no) Metode

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application